• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24738 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     Swiss Federal Office of Public Health (FOPH) Betahistine or cinnarizine with or without dimenhydrinate for Ménière’s disease/syndrome and symptoms of vestibular vertigo and/or tinnitus
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Technology Assessment programme Swabs versus tissue samples for infected diabetic foot ulcers: the CODIFI2 RCT
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Technology Assessment programme Effectiveness of Escitalopram and Nortriptyline on Depressive Symptoms in Parkinson’s disease: the ADepT-PD RCT pilot
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bevacizumab gamma (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Services and Delivery Research programme Evidence of the impact on and views of NHS staff following a colleague’s suicide to inform postvention guidance: a multi-methods study
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Repotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of technologies for the assessment of attention deficit hyperactivity disorder: a systematic review and economic model
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Repotrectinib (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2025     Haute Autorite de sante (HAS) [Next generation sequencing gene panel using circulating tumor DNA for medical lung cancer care]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elosulfase alfa (mucopolysaccharidosis IVA) – Benefit assessment according to §35a Social Code Book V]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [External beam radiotherapy delivered by ultra-hypofractionation for the treatment of prostate cancer]
2025     National Institute for Health and Care Excellence (NICE) Compression products for treating venous leg ulcers: late-stage assessment. NICE HealthTech guidance 758
2026     Health Information and Quality Authority (HIQA) Protocol for a systematic review on the association between alcohol consumption and mental health outcomes
2026     National Institute for Health and Care Excellence (NICE) Balloon cryoablation for Barrett's oesophagus. NICE HealthTech guidance 767
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Methods for evaluating digital technologies in health and social services]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [AI-based speech transcription software in health and social services: considerations for large-scale deployment]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Application of the INESSS framework : assessing the value of digital technologies in health and social services]
2026     NIHR Health Technology Assessment programme The impact and cost-effectiveness of scaling up HCV treatment for achieving elimination among people who inject drugs in England: a synopsis including evidence synthesis and economic modelling
2026     NIHR Health Technology Assessment programme Digitally enabled therapy for chronic tic disorders and Tourette Syndrome: a systematic review and economic evaluation
2026     Health Information and Quality Authority (HIQA) Protocol for modelling the risk of alcohol-attributable mortality and hospital admission in Ireland
2026     NIHR Health Technology Assessment programme Roux-en-Y gastric bypass, adjustable gastric banding or sleeve gastrectomy for severe obesity: the By-Band-Sleeve randomised controlled trial
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Symptoms and anxiety disorders in teenagers aged 12 to 17: identification, assessment and diagnostic processes, treatments, transitions in care and services]
2026     Washington Singer Press test record #3
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Revision of the information materials on colorectal cancer screening]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Management of incidental imaging findings – pancreas]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Repetitive transcranial magnetic stimulation for treatment-resistant depression in adults: effectiveness, safety and efficiency]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Drug costs – tracking trends in drug spending in Quebec from 2020 to 2025]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Appropriate use of laboratory tests – (1-3)-β-D-glucan serum testing]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Portrait of prehospital trauma triage in Québec (2013-2023) - Evaluation of the implementation of the Québec prehospital trauma triage scale (EQTPT)]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Care and services models for youth with serious behavioural disorders and mental health issues]
2026     NIHR Health Technology Assessment programme A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis
2026     NIHR Health Technology Assessment programme Establishing the safety of waterbirth for mothers and their babies: the POOL cohort study with nested qualitative component
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Newborn screening for metachromatic leukodystrophy]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between quantity of services and quality of treatment outcome in corrective surgery of Hirschsprung's disease]
2026     NIHR Health Technology Assessment programme Gabapentin as an adjunct to multimodal pain regimens in surgical patients: the GAP placebo-controlled RCT and economic evaluation
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acupuncture for migraine prophylaxis]
2026     NIHR Health Technology Assessment programme Artificial Intelligence technologies for assessing skin lesions for referral on the urgent suspected cancer pathway to detect benign lesions and reduce secondary care specialist appointments: early value assessment
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the lower age limit and frequency of early-detection colonoscopy in the colorectal cancer screening programme]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug interventions following obesity surgery: Evidence report for the S3 guideline on the diagnosis and treatment of eating disorders]
2026     NIHR Health Technology Assessment programme Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies, a multicentre, masked, randomised placebo-controlled parallel group trial (Baby-OSCAR trial)
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Psychological interventions following obesity surgery: Evidence report for the S3 guideline on the diagnosis and treatment of eating disorders]
2026     NIHR Health Technology Assessment programme Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a randomised placebo-controlled trial
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug interventions for ARFID: Evidence report for the S3 guideline on the diagnosis and treatment of eating disorders]
2026     NIHR Health Technology Assessment programme Conservative versus liberal oxygenation targets in critically ill children: the Oxy-PICU RCT
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Psychological interventions for ARFID: Evidence report for the S3 guideline on the diagnosis and treatment of eating disorders]
2026     NIHR Health Technology Assessment programme The clinical and cost-effectiveness of paravertebral blockade versus thoracic epidural blockade in reducing chronic post-thoracotomy pain: TOPIC2 RCT synopsis
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Local hyperbaric oxygen therapy for diabetic foot ulcers]
2026     NIHR Health Technology Assessment programme The clinical and cost-effectiveness of improving sleep via carer delivered strategies in people with dementia: the DREAMS START parallel multi-centre RCT
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [CR neuromodulation: Evidence report for the S3 guideline on chronic tinnitus]
2026     NIHR Health Services and Delivery Research programme Developing research resources and minimum data set for care homes’ adoption and use (DACHA)
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [TMNMT: Evidence report for the S3 guideline on chronic tinnitus]
2026     NIHR Health Technology Assessment programme Laparoscopic hysterectomy versus open abdominal hysterectomy for women with a benign gynaecological condition: the LAVA RCT
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bimodal ES: Evidence report for the S3 guideline on chronic tinnitus]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [VNS: Evidence report for the S3 guideline on chronic tinnitus]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Adhesions in the abdominal cavity: Do other measures help to relieve symptoms instead of surgery?]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [rTMS: Evidence report for the S3 guideline on chronic tinnitus]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vulvodynia (itching and pain in the vulva area): What non-drug treatment options are promising?]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Quality of sleep: Can taking melatonin as a dietary supplement, e.g. in the form of tablets, sprays or soft gums, help to improve sleep?]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [X-ray image of the lung: Can artificial intelligence support the analysis of X-ray images?]
2026     Belgian Health Care Knowledge Centre (KCE) Economic evaluation based on ‘PRECISe’, a randomised clinical trial funded by the KCE Trials programme (Study 2024-92)
2026     Belgian Health Care Knowledge Centre (KCE) Assessment of a mobile application in the rehabilitation of patients undergoing primary knee or hip arthroplasty (Study 2020-01)
2026     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Nirmatrelvir plus ritonavir (Paxlovid)]
2026     Swiss Federal Office of Public Health (FOPH) Superficial/deep heat in physiotherapy for musculoskeletal conditions
2026     Swiss Federal Office of Public Health (FOPH) Injection therapies with corticosteroids for chronic tendinopathy or enthesopathy
2026     Swiss Federal Office of Public Health (FOPH) Thermoablation for benign thyroid nodules
2026     Health Information and Quality Authority (HIQA) Rapid HTA on the use of vesicostomy buttons in children
2026     Health Technology Wales (HTW) Capsule sponge devices to detect Barrett’s oesophagus and early-stage oesophageal cancer
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Reinforced foster homes]
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Barriers and facilitators when implementing guidelines in health and social care for the elderly]
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Lattice radiotherapy in the curative or palliative treatment of deep, large-volume tumors and metastatic or unresectable disease]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Development of a decision aid for carotid revascularization surgery for carotid stenosis]
2026     Health Information and Quality Authority (HIQA) Scalable Training and Knowledge Exchange on guideline development for patients, public, and healthcare professionals (The STAKEholder Project)
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Hashimoto’s disease (thyroid inflammation): do patients who continue to experience symptoms despite treatment with drugs benefit from thyroid removal?]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Neuromuscular electrostimulation of the common peroneal nerve for the treatment of venous leg ulcers]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risk-adapted PSA and MRI screening for early detection of prostate cancer]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for updating the DMP “asthma”]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for updating the DMP “breast cancer”]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome in corrective surgery for anorectal malformations]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Parkinson’s disease: can probiotics alleviate digestive problems?]
2026     Scottish Health Technologies Group (SHTG) Virtual wards
2026     Health Information and Quality Authority (HIQA) A health technology assessment (HTA) of cochlear implants for adults with single-sided deafness
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal shockwave therapy for treating chronic skin wounds: pressure ulcers, diabetic foot ulcers, and vascular wounds (venous and/or arterial)]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Safety, clinical effectiveness and cost-effectiveness of neonatal screening for Pompe disease]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, clinical and cost-effectiveness of neonatal screening for type 1 citrullinaemia, trifunctional protein deficiency, holocarboxyl synthetase deficiency, argininosuccinic aciduria and 3-methylcrotonyl-CoA carboxylase deficiency]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Telemedicine for the follow-up of post-stroke patients]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Artificial intelligence software to detect viable tissue in stroke patients on CT or perfusion MRI of the skull]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Neurosurgical robot for electrode implantation, brain biopsies and spinal surgery]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy and safety of model-informed precision dosing of biologic agents]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of pelvic floor training during pregnancy for the prevention of pre and postnatal urinary incontinence]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Laboratory animals – farm animals: Evidence report for the S3 guideline on allergic rhinitis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Flour: Evidence report for the S3 guideline on allergic rhinitis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pets-rodents: Evidence report for the S3 guideline on allergic rhinitis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pollen: Evidence report for the S3 guideline on allergic rhinitis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [House dust mites: Evidence report for the S3 guideline on allergic rhinitis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Test quality: Evidence report for the S3 guideline on allergic rhinitis]
2026     NIHR Health Technology Assessment programme Relative and bedside nurse assessment of comfort and communication during propofol, dexmedetomidine, or clonidine-based sedation: pre-planned analysis within the A2B RCT
2026     NIHR Health Services and Delivery Research programme A randomised feasibility trial of an intervention involving mental health support workers as link workers to improve dental visiting in people with severe mental illness: The Mouth Matters in Mental Health Study
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP "Chronic obstructive pulmonary disease (COPD)]